Observation or toripalimab after chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is for people with advanced esophageal cancer that hasn't spread far. After initial treatment with chemotherapy, immunotherapy, and radiation, you'll either get toripalimab or just be watched to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of esophageal cancer called squamous cell carcinoma that is not curable with surgery.
- Your cancer must not have gotten worse after 2–4 rounds of chemo-immunotherapy plus radiation.
- You must be between 18 and 75 years old.
- You must be in good overall health, able to care for yourself, and have adequate organ function.
- You cannot have other serious medical conditions or a history of autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding an immunotherapy drug (toripalimab) to chemotherapy and low-dose radiation for people with esophageal cancer that did not shrink after initial treatment. The goal is to see if this combination can help when standard therapy stops working.
This trial tests whether giving immunotherapy after surgery can help prevent cancer from returning in patients with esophageal squamous cell carcinoma. It is for people who have already received chemotherapy and immunotherapy before surgery and had surgery to remove the cancer, but still had some cancer cells found in the removed tissue.
This trial compares two treatments given before surgery for esophageal cancer. One combines an immunotherapy drug (Toripalimab) with chemotherapy (nab-paclitaxel and platinum). The other uses a different standard chemotherapy regimen (DCF). The goal is to see which is better at shrinking tumors and improving outcomes for patients with resectable, locally advanced esophageal squamous cell carcinoma.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.